Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Nouscom
Entity

Nouscom

Tracked across 1 events · 20 articles · First seen Aug 06, 2026 · Last active Aug 10, 2026

Sentiment
80
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 80
Tech
Lynch syndrome colon cancer vaccines advance
Researchers are developing vaccines to prevent colon cancer in people with Lynch syndrome, an inherited condition that greatly increases the risk of colorectal and other cancers. At least three experimental vaccines are in development: Nouscom's…
Impact: Nouscom's vaccine showed promising early results in reducing precancerous polyps in Lynch syndrome patients, positioning the company as a leader in preventive cancer vaccines.
Aug 06, 2026 · 20 articles
Key Actions (2)
90 Nouscom developed vaccineLynch syndrome colon...
60 Eduardo Sánchez expects larger study NouscomLynch syndrome colon...
ERGEN INTELLIGENCE
Track Nouscom live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.